683 Capital Management »

Kymera Therapeutics shares owned by 683 Capital Management

Quarter-by-quarter ownership of Kymera Therapeutics (KYMR) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Kymera Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kymera Therapeutics held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kymera Therapeutics by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.4M 30k 114.67

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. Put Option (LLY)
NVIDIA Corporation Put Option (NVDA)
Spdr Series Trust St Str Sp Biot Put Option (XBI)
Capital One Financial (COF)
Abbvie Put Option (ABBV)
Carvana Cl A (CVNA)
Madrigal Pharmaceuticals Put Option (MDGL)
Anaptysbio Inc Common (ANAB)
Alnylam Pharmaceuticals (ALNY)
Uniqure Nv SHS (QURE)
Kaspi Kz Jsc Sponsored Ads (KSPI)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Becton, Dickinson and (BDX)
Molina Healthcare (MOH)

View all positions for 683 Capital Management

Top funds holding Kymera Therapeutics

FMR
Baker Bros. Advisors
venBio Select Advisor
T. Rowe Price Associates
BlackRock
BVF
Wellington Management Company
Vanguard Portfolio Management
Siren
Vanguard Capital Management
Atlas Venture Life Science Advisors
State Street Corporation
Geode Capital Management
Capital Research Global Investors
Goldman Sachs Group

View all funds holding Kymera Therapeutics